Compare EPR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | FOLD |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.4B |
| IPO Year | 1997 | 2007 |
| Metric | EPR | FOLD |
|---|---|---|
| Price | $58.44 | $14.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $57.94 | $26.11 |
| AVG Volume (30 Days) | 825.5K | ★ 7.2M |
| Earning Date | 02-25-2026 | 02-18-2026 |
| Dividend Yield | ★ 6.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $707,150,000.00 | $598,704,000.00 |
| Revenue This Year | $5.12 | $21.70 |
| Revenue Next Year | $3.22 | $18.91 |
| P/E Ratio | $25.60 | ★ N/A |
| Revenue Growth | 3.73 | ★ 21.28 |
| 52 Week Low | $41.75 | $5.51 |
| 52 Week High | $61.24 | $14.38 |
| Indicator | EPR | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 69.93 | 79.28 |
| Support Level | $56.74 | $14.30 |
| Resistance Level | $58.58 | $14.36 |
| Average True Range (ATR) | 1.23 | 0.03 |
| MACD | 0.24 | -0.09 |
| Stochastic Oscillator | 87.47 | 75.00 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.